Track market-moving stories before they get noisy

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced that StarGuide GX,i its new digital 4D CZT SPECT/CT technology, is 510(k) pending with the U.S. Food and Drug Administration (FDA). Building on the system's recent CE Mark, this milestone is a step towards expanding access to advanced molecular imaging technologies in the United States and marks a significant moment in molecular imaging's evolution – aiming to empower clinicians with a high-performance, general purpose scanner to help pers.

Key Takeaways GEHC's Photonova Spectra received CE Mark, expanding access across Europe and other CE markets.Deep Silicon enables ultra-high-definition imaging, spectral imaging and fast, wide-coverage scans.GEHC is collaborating with European institutions to evaluate Photonova Spectra across specialties. GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced that its Photonova Spectra advanced photon-counting computed tomography (PCCT) system has received CE Mark, expanding access to the technology across Europe and other CE Mark-observing markets. The regulatory milestone follows FDA 510(k) clearance and Japanese regulatory approval in March 2026.

Powered by GEHC’s proprietary Deep Silicon detector technology, Photonova Spectra is designed to deliver ultra-high definition imaging, on-demand spectral and spatial imaging, and fast, wide-coverage acquisition to support disease detection, characterization and monitoring.

Per management, clinicians across Europe are seeking imaging solutions that can address growing demand while enhancing diagnostic confidence. Deep Silicon photon-counting CT combines high image clarity with the efficiency required for consistent clinical use. With the CE Mark for Photonova Spectra, GE HealthCare is expanding access to the technology among European care teams, combining Deep Silicon, ultra-high-definition imaging and wide detector coverage to support fast and comprehensive acquisitions.

GEHC Stock Trend Following the NewsGEHC stock has lost 1.1% since the announcement on Monday. Year to date, the stock has fallen 14.2% compared with the industry’s 17% decline. However, the S&P 500 has risen 10.8% in the same timeframe.

The CE Mark expands GEHC’s commercial opportunity in the growing photon-counting CT market and strengthens its premium imaging portfolio. The system’s regulatory progress across the United States, Japan, Europe and other CE Mark-recognizing markets demonstrates the company’s ability to advance innovative imaging technologies. Increasing commercial opportunities, supported by clinical collaborations and strong innovation capabilities, could contribute to revenue growth and strengthen GE HealthCare’s imaging business.

GEHC currently has a market capitalization of $32.17 billion.

Image Source: Zacks Investment Research

More on Photonova SpectraA major differentiator of Photonova Spectra is its proprietary Deep Silicon detector technology, which enables precise photon energy measurement and supports advanced spectral imaging. The system provides 80 mm detector coverage and a rapid 0.23-second rotation speed, enabling fast acquisitions while improving visualization of subtle tissue variations, small lesions and vascular structures. Its one-scan, full-fidelity approach allows spectral and spatial imaging to be accessed on demand without requiring exam-specific protocols.

Using NVIDIA’s accelerated computing platform and CUDA-optimized reconstruction, the system is engineered to manage data volumes up to 50 times greater than conventional CT while delivering timely images. Automated features, including Auto Positioning and the CT ONE operator environment, further aim to improve consistency and simplify CT workflows.

Its clinical potential spans multiple specialties, including neurology, oncology, musculoskeletal, thoracic imaging and cardiology. Applications include visualization of tiny anatomical structures, lesion characterization, iodine mapping, detection of small fractures, high-detail chest imaging, and assessment of coronary stents, plaque and myocardium.

GEHC is also collaborating with UZ Brussel – Vrije Universiteit Brussel and Rigshospitalet to evaluate Photonova Spectra across cardiology, oncology, neurology, spectral imaging and musculoskeletal imaging. These collaborations could generate clinical evidence and support research into quantitative imaging, tissue characterization and spectral biomarkers, broadening the system’s clinical applications.

Industry Prospects Favoring the MarketGoing by the data provided by Business Research Insights, the global photon counting CT market is valued at $0.5 billion in 2026 and is expected to witness a CAGR of 29.4% through 2035.

Factors like regulatory approvals, strategic collaborations, rising demand for advanced diagnostic imaging and competitive innovation are boosting the market’s growth.

Other NewsGE HealthCare recently announced three additions to its Vivid cardiovascular ultrasound portfolio — Vivid Explorer, Vivid Advanced and Vivid Focus — designed to support cardiac imaging and workflow needs across different care settings.

All three new systems use cSound, a software-based imaging architecture designed to enhance contrast, resolution and tissue visualization. AI-enabled tools, including AI Auto Measure 2D, Easy AutoEF, Easy AFI LV and AI Cardiac Auto Doppler, are designed to reduce manual steps and simplify cardiac measurements.

GEHC’s Zacks Rank & Key PicksCurrently, GEHC carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) recently achieved CE Mark for Photonova Spectra,i an advanced photon-counting computed tomography (PCCT) system with the company’s proprietary Deep Silicon™ detector technology. The regulatory milestone expands access and enables clinical adoption of the technology in CE Mark–observing countries and underscores GE HealthCare’s commitment to purposeful, customer-driven innovation in computed tomography (CT).

"We are proud to deliver this new generation of photon-counting CT to the clinicians and patients around the world it was intentionally designed to serve." -- Chad Rowland, Executive Director, Global CT, GE HealthCare.

Share “We are proud to deliver this new generation of photon-counting CT to the clinicians and patients around the world it was intentionally designed to serve,” shares Chad Rowland, Executive Director, Global CT, GE HealthCare. “At its core is our Deep Silicon detector technology, which enables Photonova Spectra to capture remarkably detailed, spectral information in every scan. That level of clarity and consistency aims to make a meaningful difference in both cutting-edge research and day‑to‑day care – from helping teams see subtle findings confidently to reducing steps across a wide range of exams. Ultimately, this innovative technology was created to advance imaging as well as support the people who rely on it.”

As healthcare providers navigate rising patient volumesii and increasing diagnostic complexity,iii clinicians need clear, timely answers to inform decisions across care pathways. Photonova Spectra was intentionally engineered to help clinicians address these realities.

By harnessing the full potential of GE HealthCare’s proprietary Deep Silicon detector technology, the system’s ultra-high definition (UHD) imaging is designed to work with wide coverage, enabling fast acquisition speeds and the precise visualization of subtle tissue variations, small lesions and vascular structures. With on-demand spectral and spatial imaging for every scan and a one protocol setup for many exams, Photonova Spectra also seeks to empower clinicians to detect, characterize and monitor disease with confidence as well as reducing complexity and supporting efficiency.

“Deep Silicon brings a meaningful evolution to photon-counting CT. Silicon's unique properties as a semiconductor enables precise photon energy measurement, helping power advanced spectral imaging capabilities,” adds Johan de Mey, MD, PhD, Chair of Radiology, UZ Brussel - Vrije Universiteit Brussel. “For us, that may offer new opportunities to differentiate materials like iodine, calcium and fat, as well as provide image quality that holds up even in challenging patient scenarios. Additionally, with Photonova Spectra’s rapid 0.23‑second rotation speed and 80 mm detector coverage, we can achieve fast, motion‑free acquisitions across care areas, helping ensure that detail and diagnostic confidence aren’t compromised. These advancements aim to provide a more reliable picture of how a condition is evolving or whether a treatment is truly working, supporting more timely and informed decisions for every patient.”

The clinical potential of Photonova Spectra with Deep Silicon spans a wide range of specialties, seeking to unlock new levels of clarity, detail, and diagnostic confidence with the technology's design, including:

Neurology: Excellent visualization of tiny structures like the inner ear and clear delineation between brain grey and white matter at the same time.iv Oncology: Clear lesion characterization and precise quantification due to the system’s Deep Silicon detectors – helping clinicians make confident decisions for cancer detection. Its iodine mapping also aims to help clinicians distinguish oncological findings and support treatment monitoring. Musculoskeletal imaging: Impressive visualization of small fractures and bone marrow edema, supporting detailed assessments for orthopedic care. Thoracic imaging: Ultra-high definition chest scans, capable of revealing fine details with exceptional clarity. Cardiology: Wide coverage that provides robust imaging, while combining ultra-high definition and spectral imaging to enable in-stent lumen assessment, plaque characterization and myocardial assessment. Photonova Spectra’s advanced photon-counting architecture and Deep Silicon detector design also aim to open new possibilities for research, including quantitative imaging, tissue characterization, and spectral biomarker discovery. By enabling richer spectral data, the system may also allow researchers to explore novel clinical applications and imaging protocols that were previously constrained by conventional CT technology.

“Across Europe, clinicians are looking for imaging solutions that keep pace with rising demand while elevating diagnostic confidence,” says Catherine Estrampes, President & CEO, Global Markets, GE HealthCare. “Deep Silicon photon‑counting CT gives them both – the clarity needed to see what truly matters and the efficiency required to deliver it consistently. With CE Mark for Photonova Spectra, we’re bringing this technology to European care teams with the added strengths of Deep Silicon, ultra‑high definition imaging, and wide detector coverage to help support fast, robust acquisitions. It’s about giving clinicians tools that help them move quickly and decisively and giving their patients the reassurance that their care is guided by the best information possible.”

Photonova Spectra is intentionally designed to manage the significant data volumes generated by photon-counting CT, harnessing up to 50 times more datav than conventional CT by using NVIDIA’s accelerated computing platform and CUDA-optimized reconstruction to turn rich spectral datasets into timely, clinically actionable images while helping maintain smooth, efficient workflows.

Workflow efficiency is further supported by a one-scan, universal full fidelity approach intended to reduce exam-specific protocols and enable automated reconstruction of ultra-high definition spectral images on demand. The CT ONE operator environment and automated features – including Auto Positioning – are designed to help improve consistency across GE HealthCare systems and simplify the overall CT workflow.

Advancing innovation through global collaboration

Additionally, GE HealthCare is expanding collaborations across clinical disciplines to further evaluate Photonova Spectra and accelerate new discoveries:

UZ Brussel – Vrije Universiteit Brussel (Brussels, Belgium): A premier European academic medical center collaborating to assess the advanced capabilities of Photonova Spectra across multiple clinical domains, including cardiology, oncology, and spectral imaging. In particular, the collaboration will support the evaluation of advanced imaging applications, generating valuable clinical evidence and optimizing imaging protocols to facilitate broader adoption in routine clinical practice. Rigshospitalet (Copenhagen, Denmark): A leading university hospital for highly specialized diagnostics and treatments collaborating to explore broad the clinical applications of GE HealthCare’s photon-counting CT system. The collaboration will include a focus on low-dose imaging, enhanced tissue characterization, and the use of spectral data across complex clinical cases such as neurology, cardiology, oncology, and musculoskeletal imaging. These collaborations and the advanced architecture of Photonova Spectra could open new avenues for research in quantitative imaging, tissue characterization, and spectral biomarker development.

With CE Mark now achieved, GE HealthCare will begin commercial activities in countries that observe CE Mark.

News of Photonova Spectra’s latest regulatory achievement quickly follows its 510(k) clearance by the U.S. Food and Drug Administration (FDA) and Japanese regulatory approval in March 2026 – further demonstrating GE HealthCare’s ability to move breakthrough innovation from introduction to regulatory validation with speed and discipline.

Photonova Spectra is a result of the company’s more than $5 billion innovation investment, leading to a wave of transformational products across the portfolio which combined are expected to drive 1-2 percent revenue growth.

For more information on GE HealthCare’s new Photonova Spectra photon-counting CT with Deep Silicon detectors, please visit gehealthcare.com.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conference: Wells Fargo 21st Annual Health Conference – Wednesday, September 9, 2026 at 10:15 am ET/9:15am CT A webcast for the event can be accessed on the GE HealthCare website: https://investor.gehealthcare.com/news-events/events at the date and time listed above. About GE HealthCare Technologies Inc. GE HealthCare is a leading global health.

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced three additions to its Vivid™ cardiovascular ultrasound portfolio – Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus.

It has been about a month since the last earnings report for GE HealthCare Technologies (GEHC - Free Report) . Shares have added about 3.6% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is GE HealthCare due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for GE HealthCare Technologies Inc. before we dive into how investors and analysts have reacted as of late.

GEHC Q2 Earnings & Revenues Beat EstimatesGE HealthCare reported second-quarter 2026 adjusted earnings per share of $1.13, which beat the Zacks Consensus Estimate of $1.04 by 8.7%. The bottom line increased 6.6% year over year, aided by commercial execution, pricing and productivity gains.

GAAP EPS in the quarter was $1.24, up 16.5% from the year-ago level.

GEHC's Revenue Growth Gains MomentumRevenues of $5.29 billion increased 5.7% year over year on a reported basis and 3.5% organically. The top line surpassed the Zacks Consensus Estimate by 0.7%. Revenue growth was led by Pharmaceutical Diagnostics (PDx) and Advanced Imaging Solutions (AIS), along with strength in the United States, EMEA and Rest of World markets. However, growth was partially offset by a decline in the Patient Care Solutions (PCS) segment.

Total company orders increased 11.1% year over year organically. The book-to-bill ratio was 1.15X, indicating rising orders compared to shipments, with backlog reaching a record $23.9 billion. Management cited order growth across every segment, supported by strong commercial execution and adoption of new products.

GE HealthCare’s Q2 Segmental DetailsPharmaceutical Diagnostics revenues increased 15.6% year over year to $843 million. Growth was supported by higher contrast-media volumes, pricing and U.S. radiopharmaceutical demand. Segment EBIT was $250 million, up 16.9% year over year.

Advanced Imaging Solutions revenues increased 7.9% year over year to $3.77 billion. Growth was supported by CardioVascular and Interventional Solutions, computed tomography and Molecular Imaging. Segment EBIT was $525 million, up 15.4% year over year.

Patient Care Solutions revenues declined 13.3% year over year to $675 million. Management attributed the decline primarily to operational and fulfillment challenges, despite strong first-half orders that indicated healthy customer demand.

GEHC's Margin and Cash Flow ImproveNet income margin expanded 90 basis points to 10.6%. However, net income margin was negatively impacted due to PCS weakness and inflation in memory chips, oil and freight costs.

Cumulative cash flow from operating activities at the end of the second quarter was $458 million compared with $344 million a year ago.

GE HealthCare’s Financial PositionGEHC exited the second quarter with cash, cash equivalents and restricted cash of $2.11 billion compared with $2.28 billion in the previous quarter.

Total assets increased to $37.25 billion from $37.12 billion on a sequential basis.

GE HealthCare Reaffirms 2026 GuidanceGE HealthCare reaffirmed its guidance for 2026.

The company still expects organic revenue growth of 3-4% in 2026. It anticipates adjusted earnings per share to be in the range of $4.80-$5.00, implying 4.6%-9.0% year-over-year growth, as expected previously.

Management anticipates approximately $250 million of inflation associated with memory chips, oil and freight and other components, but expects pricing and cost actions to offset more than half of that impact.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates revision.

VGM ScoresCurrently, GE HealthCare has a subpar Growth Score of D, a grade with the same score on the momentum front. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, GE HealthCare has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry PlayerGE HealthCare is part of the Zacks Medical - Products industry. Over the past month, Abbott (ABT - Free Report) , a stock from the same industry, has gained 5.7%. The company reported its results for the quarter ended June 2026 more than a month ago.

Abbott reported revenues of $12.59 billion in the last reported quarter, representing a year-over-year change of +13%. EPS of $1.31 for the same period compares with $1.26 a year ago.

Abbott is expected to post earnings of $1.43 per share for the current quarter, representing a year-over-year change of +10%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.2%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Abbott. Also, the stock has a VGM Score of B.

Key Takeaways GEHC's Q2 organic orders rose 11.1%, with book-to-bill at 1.15X and backlog reaching a record $23.9B.GE HealthCare entered Q3 with nearly 85% of equipment revenue secured and reaffirmed 3%-4% growth.GEHC must improve PCS execution and offset about $250M of expected 2026 inflation to support margins. GE HealthCare Technologies Inc. (GEHC - Free Report) delivered a notable demand signal in the second quarter, with organic orders rising 11.1% year over year. Book-to-bill reached 1.15X and backlog climbed to a record $23.9 billion.

The key question is how much of that demand can convert into profitable revenues. Backlog visibility is improving, but execution in Patient Care Solutions and inflation remain important constraints.

GEHC’s Order Surge Was Broad BasedManagement said second-quarter order growth was broad based across every segment and included no material one-time items. The two-year order-growth stack exceeded 7%, supporting the view that demand strength extended beyond one quarter.

Orders also rose across Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions. That breadth matters because it reduces dependence on a single product category as GEHC moves through a multi-year innovation cycle.

GE HealthCare Enters Q3 With Revenue SecuredNearly 85% of equipment revenue entering the third quarter was already secured. GE HealthCare expects third-quarter organic revenue growth of 3% to 4%, providing a clearer bridge from backlog to near-term sales conversion.

The company also reaffirmed full-year organic revenue growth guidance of 3% to 4%. Execution remains the deciding factor, particularly as longer-cycle equipment orders require manufacturing, installation and customer-site readiness before they become revenues.

Image Source: Zacks Investment Research

GEHC’s Backlog Could Extend Into 2027The $23.9 billion backlog was up $2.6 billion year over year. Management said some of the strongest order growth came from longer-cycle radiology products, which are expected to contribute more meaningfully to revenues in 2027.

That timing gives GEHC visibility beyond the current year, but it also shifts attention toward conversion quality. Investors will need to watch whether backlog growth translates into sustainable revenue gains rather than simply extending delivery schedules.

GE HealthCare’s New Products Can Lift the MixPhotonova Spectra, True Definition DL and Vivid Pioneer are part of GE HealthCare’s imaging and ultrasound innovation cycle. Management said Vivid Pioneer is generating a higher gross margin than the prior platform, helped by lower manufacturing costs and AI-enabled features that support pricing.

Koninklijke Philips N.V. (PHG - Free Report) is also refreshing its imaging portfolio, including AI-powered magnetic resonance imaging and image-guided therapy technologies. Medtronic plc (MDT - Free Report) is expanding real-time AI capabilities in surgery, illustrating how product innovation and workflow productivity remain central competitive themes across medical technology.

GEHC Must Turn Orders Into Profitable RevenuePatient Care Solutions shows why strong demand alone is insufficient. Second-quarter PCS revenues declined 13.3% year over year and segment EBIT was negative, with operational and fulfillment challenges limiting backlog conversion.

Inflation adds another hurdle. GE HealthCare continues to expect about $250 million of 2026 inflation tied to memory chips, oil, freight and other components. Pricing, productivity and improved shipment velocity therefore remain important to converting backlog into margin expansion.

GEHC’s Near-Term Signal Supports the Backlog StoryGEHC’s record backlog and broad order growth improve revenue visibility, but the investment theme still depends on execution. The company must convert demand while stabilizing PCS and offsetting input-cost pressure.

GEHC currently carries a Zacks Rank #2 (Buy). Its Value Score of B is favorable for value-oriented investors, while the Growth Score of D and Momentum Score of F are weaker. The VGM Score of C reflects a mixed blend across value, growth and momentum, reinforcing the need to balance the positive near-term Rank with execution risks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Barrow Hanley Mewhinney & Strauss LLC grew its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,455,814 shares of the company’s stock after purchasing an additional 1,571,226 shares during the period. GE HealthCare Technologies makes up 2.6% of Barrow Hanley Mewhinney & Strauss LLC’s investment portfolio, making the stock its 3rd largest position. Barrow Hanley Mewhinney & Strauss LLC owned 2.98% of GE HealthCare Technologies worth $861,307,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in GEHC. Vanguard Group Inc. lifted its position in shares of GE HealthCare Technologies by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 52,275,767 shares of the company’s stock worth $4,287,658,000 after purchasing an additional 267,058 shares in the last quarter. Auto Owners Insurance Co boosted its position in shares of GE HealthCare Technologies by 9,525.4% during the 4th quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock worth $278,725,000 after acquiring an additional 33,629,559 shares in the last quarter. Dodge & Cox increased its stake in GE HealthCare Technologies by 13.4% in the fourth quarter. Dodge & Cox now owns 31,211,229 shares of the company’s stock valued at $2,559,945,000 after purchasing an additional 3,693,918 shares during the last quarter. Capital Research Global Investors raised its stake in GE HealthCare Technologies by 1.6% during the 4th quarter. Capital Research Global Investors now owns 25,362,352 shares of the company’s stock worth $2,080,248,000 after acquiring an additional 389,796 shares in the last quarter. Finally, State Street Corp increased its position in shares of GE HealthCare Technologies by 2.0% during the fourth quarter. State Street Corp now owns 20,049,677 shares of the company’s stock worth $1,644,475,000 after purchasing an additional 401,932 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

GE HealthCare Technologies Stock Performance NASDAQ GEHC opened at $74.82 on Monday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.26 and a quick ratio of 0.97. The company has a market cap of $33.80 billion, a P/E ratio of 17.16, a P/E/G ratio of 2.16 and a beta of 0.69. GE HealthCare Technologies Inc. has a 12 month low of $58.75 and a 12 month high of $89.77. The company has a 50-day moving average of $66.61 and a 200-day moving average of $69.53.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.04 by $0.09. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.26 billion. During the same period in the previous year, the company earned $1.06 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. As a group, equities analysts predict that GE HealthCare Technologies Inc. will post 4.93 earnings per share for the current year. GE HealthCare Technologies Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Friday, July 24th were paid a dividend of $0.035 per share. This represents a $0.14 annualized dividend and a yield of 0.2%. The ex-dividend date was Friday, July 24th. GE HealthCare Technologies’s payout ratio is currently 3.21%.

Wall Street Analyst Weigh In GEHC has been the topic of a number of recent research reports. Argus cut their target price on shares of GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Royal Bank Of Canada initiated coverage on GE HealthCare Technologies in a report on Tuesday, June 23rd. They issued an “outperform” rating and a $80.00 price target for the company. UBS Group boosted their price objective on shares of GE HealthCare Technologies from $67.00 to $73.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Citigroup upped their target price on GE HealthCare Technologies from $69.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, July 30th. Finally, BMO Capital Markets initiated coverage on shares of GE HealthCare Technologies in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $70.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, GE HealthCare Technologies has an average rating of “Hold” and a consensus target price of $77.73.

Get Our Latest Report on GEHC

(Free Report)

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.

Read More Five stocks we like better than GE HealthCare Technologies VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report).

Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

LOS ANGELES, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company’s possible violations of the federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.

On July 23, 2026, the Company announced its Chief Financial Officer, ​Jay Saccaro, will step ‌down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice
Persons with non-public information regarding GE HealthCare Technologies Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP (“GPWR”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPWR has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPWR was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.

With four offices across the country, GPWR’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

LOS ANGELES, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.  

What Is The Investigation About?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.

On July 23, 2026, the Company announced its Chief Financial Officer, ​Jay Saccaro, will step ‌down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.

Contact Us To Participate or Learn More:
If you purchased GE HealthCare Technologies Inc. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.  
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007
[email protected]
www.frankcruzlaw.com

GE HealthCare said on Tuesday it had appointed William Grogan chief financial officer, ​effective September 14, succeeding Jay Saccaro after ‌he stepped down last month.

GE HealthCare Technologies (GEHC - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

As such, the Zacks rating upgrade for GE HealthCare is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

For GE HealthCare, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for GE HealthCareThis medical technology company is expected to earn $4.93 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for GE HealthCare. Over the past three months, the Zacks Consensus Estimate for the company has increased 1%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of GE HealthCare to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: GE HealthCare Technologies (GEHC - Free Report) Chicago, IL-based GE HealthCare Technologies, a leading global medtech company, operates across four primary segments — Imaging, Ultrasound (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Headquartered in Chicago, the company has a diversified portfolio of advanced medical imaging systems, ultrasound devices, monitoring equipment, and a growing radiopharmaceuticals pipeline. With a mission to deliver precision care, GEHC continues to pivot from a traditional equipment vendor toward an integrated solutions provider, combining hardware, software, digital analytics, and pharmaceuticals.

GEHC is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Medical stock. GEHC has a Momentum Style Score of B, and shares are up 8.7% over the past four weeks.

For fiscal 2026, six analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.04 to $4.93 per share. GEHC boasts an average earnings surprise of +0.9%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, GEHC should be on investors' short list.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.94% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: GE HealthCare Technologies (GEHC - Free Report) Chicago, IL-based GE HealthCare Technologies, a leading global medtech company, operates across four primary segments — Imaging, Ultrasound (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Headquartered in Chicago, the company has a diversified portfolio of advanced medical imaging systems, ultrasound devices, monitoring equipment, and a growing radiopharmaceuticals pipeline. With a mission to deliver precision care, GEHC continues to pivot from a traditional equipment vendor toward an integrated solutions provider, combining hardware, software, digital analytics, and pharmaceuticals.

GEHC is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 14.26; value investors should take notice.

Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.04 to $4.93 per share. GEHC also boasts an average earnings surprise of +0.9%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, GEHC should be on investors' short list.

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the launch of Invenia™ ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue™, a redesigned enterprise viewer that recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, expanding its breast imaging portfolio with solutions designed to support supplemental screening for women with dense breasts and provide more flexible enterprise-wide exam review. Together, these new solutions aim to help breast i.

, /PRNewswire/ -- Law Offices of Howard G. Smith continues its investigation on behalf of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ:GEHC) investors concerning the Company's possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened? 
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed "profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier" and that "[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue."

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.

On July 23, 2026, the Company announced its Chief Financial Officer, Jay Saccaro, will step ‌down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.

Contact Us To Participate or Learn More:

If you purchased GE HealthCare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com 

SOURCE Law Offices of Howard G. Smith

, /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ:GEHC) on behalf of investors concerning the Company's possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. 

What Is The Investigation About?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed "profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier" and that "[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue."

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%,  to close at $59.49 per share on April 29, 2026.

On July 23, 2026, the Company announced its Chief Financial Officer, Jay Saccaro, will step ‌down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.

Contact Us To Participate or Learn More: 
If you purchased GE HealthCare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected] 
Visit our website at: www.frankcruzlaw.com. 
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

BENSALEM, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.

On July 23, 2026, the Company announced its Chief Financial Officer, ​Jay Saccaro, will step ‌down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.

Contact Us To Participate or Learn More:
If you purchased GE HealthCare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

Posted by Defense World Staff on Jul 30th, 2026

Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC – Get Free Report) gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $64.11, but opened at $69.32. GE HealthCare Technologies shares last traded at $71.8030, with a volume of 2,822,886 shares.

The company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.04 by $0.09. GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.26 billion. During the same period in the previous year, the company posted $1.06 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year.

GE HealthCare Technologies Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Friday, July 24th will be paid a $0.035 dividend. The ex-dividend date is Friday, July 24th. This represents a $0.14 dividend on an annualized basis and a yield of 0.2%. GE HealthCare Technologies’s payout ratio is presently 3.35%.

More GE HealthCare Technologies News Here are the key news stories impacting GE HealthCare Technologies this week:

Positive Sentiment: GE HealthCare reported adjusted earnings of $1.13 per share, exceeding the $1.04 analyst consensus, while revenue reached approximately $5.29 billion versus expectations of $5.26 billion. Revenue rose about 5.8% year over year, helped by increased orders and healthy demand. GE HealthCare beats quarterly profit estimates on strong imaging demand, tariff refunds Positive Sentiment: Orders grew approximately 11% organically, book-to-bill reached a post-spin-off record near 1.15, and backlog climbed to a record $23.9 billion. The metrics provide stronger future revenue visibility and suggest hospitals are resuming capital investments in imaging and diagnostic infrastructure. GEHC Q2 Earnings and Revenues Beat Estimates Positive Sentiment: Pharmaceutical Diagnostics delivered particularly strong growth, while imaging demand remained healthy. Management also said it is reviewing strategic alternatives for the underperforming Patient Care Solutions business, potentially allowing GE HealthCare to improve margins by restructuring or divesting the unit. GE HealthCare reports second quarter 2026 financial results Positive Sentiment: BTIG Research raised its GEHC price target from $75 to $79 and assigned a “Buy” rating, reinforcing the positive earnings reaction and suggesting additional upside based on the firm’s estimates. BTIG raises GE HealthCare price target Neutral Sentiment: Unusually high call-option activity showed traders purchasing roughly 8,956 contracts, about 45% above average. This reflects bullish speculative interest but does not directly change GE HealthCare’s fundamentals. Negative Sentiment: The earnings beat benefited from a tariff refund and a lower tax rate, which may not recur. Adjusted EBIT margins also contracted by roughly 40 basis points to about 14.2%, with Patient Care Solutions reporting a sharp organic revenue decline and negative EBIT. Analyst Upgrades and Downgrades A number of research firms have weighed in on GEHC. BTIG Research raised their price objective on shares of GE HealthCare Technologies from $75.00 to $79.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company cut their price target on shares of GE HealthCare Technologies from $97.00 to $75.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Jefferies Financial Group reduced their price target on shares of GE HealthCare Technologies from $105.00 to $90.00 in a research report on Thursday, April 30th. BMO Capital Markets started coverage on shares of GE HealthCare Technologies in a report on Wednesday, July 8th. They issued a “market perform” rating and a $70.00 price objective for the company. Finally, Evercore set a $80.00 price objective on GE HealthCare Technologies in a research report on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $76.59.

Read Our Latest Stock Analysis on GE HealthCare Technologies

Insider Transactions at GE HealthCare Technologies In other news, CFO James Saccaro bought 3,310 shares of the stock in a transaction on Friday, May 1st. The shares were bought at an average price of $60.60 per share, with a total value of $200,586.00. Following the completion of the acquisition, the chief financial officer owned 87,471 shares in the company, valued at $5,300,742.60. The trade was a 3.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Rodney F. Hochman bought 1,618 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was purchased at an average cost of $62.03 per share, for a total transaction of $100,364.54. Following the completion of the transaction, the director directly owned 1,618 shares of the company’s stock, valued at approximately $100,364.54. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 15,928 shares of company stock worth $1,005,761 in the last three months. 0.36% of the stock is owned by insiders.

Hedge Funds Weigh In On GE HealthCare Technologies A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wedge Capital Management L L P NC grew its position in GE HealthCare Technologies by 27.8% during the second quarter. Wedge Capital Management L L P NC now owns 461,283 shares of the company’s stock valued at $29,527,000 after buying an additional 100,462 shares during the period. Northside Capital Management LLC increased its holdings in GE HealthCare Technologies by 26.5% during the second quarter. Northside Capital Management LLC now owns 241,923 shares of the company’s stock valued at $15,485,000 after buying an additional 50,634 shares during the last quarter. Investors Research Corp bought a new position in GE HealthCare Technologies in the second quarter worth approximately $288,000. Tema ETFs LLC raised its position in GE HealthCare Technologies by 10.4% in the second quarter. Tema ETFs LLC now owns 9,214 shares of the company’s stock worth $590,000 after acquiring an additional 870 shares during the period. Finally, Generali Investments Management Co LLC boosted its stake in shares of GE HealthCare Technologies by 5.1% during the 2nd quarter. Generali Investments Management Co LLC now owns 6,098 shares of the company’s stock worth $390,000 after acquiring an additional 298 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Performance The business’s 50-day moving average price is $63.83 and its 200-day moving average price is $70.69. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.95 and a current ratio of 1.22. The stock has a market cap of $32.71 billion, a P/E ratio of 17.20, a P/E/G ratio of 1.74 and a beta of 0.72.

GE HealthCare Technologies Company Profile (Get Free Report)

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.

Recommended Stories Five stocks we like better than GE HealthCare Technologies Why SK hynix Could Be the Best AI Chip Stock to Buy Now Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Why Bloom Energy May Be the Most Important AI Infrastructure Stock Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEErste Group Bank Brokers Increase Earnings Estimates for MU

NEXT HEADLINE »Manhattan Associates (NASDAQ:MANH) Shares Gap Up After Strong Earnings

Shares in GE Healthcare (GEHC +11.36%) were higher by 12% at around 11 a.m. today on the back of its second-quarter earnings report. It's been a difficult year for the company, but the latest results, particularly the order book, are signaling an improvement ahead. Here's why.

GE Healthcare's recovery is in progress The second-quarter earnings came in ahead of expectations. Still, management reiterated its previous full-year guidance: organic revenue growth of 3%-4%, adjusted EPS of $4.80-$5.00, and free cash flow (FCF) of approximately $1.6 billion.It's superficially unimpressive, but the devil is in the detail of the order book, and specifically the 11.1% growth in orders, taking its book-to-bill ratio to 1.15 times, and its backlog to $23.9 billion.

Today's Change

(

11.36

%) $

7.28

Current Price

$

71.39

To understand why this is so important, you have to go back to the first-quarter results, when management was forced to lower its full-year earnings guidance on the back of a $250 million increase in costs from memory chips, oil, freight, and raw materials. The cost increase is problematic for a company like GE Healthcare, which has relatively long sales cycles, because it can't react quickly to raise prices and has to work through a backlog secured at prices before the cost inflation hit.

Image source:Getty Images.

Why the orders growth is great news Consequently, the orders growth implies an improvement in pricing. In addition, CFO James Saccaro said the company's cost actions "hold in the second quarter," and he expects them "to contribute more meaningfully to margin in the second half of the year and in 2027." CEO Peter Arduini noted that several new products launched, including those with embedded AI, would also drive pricing improvements.

All told, the market is pricing in improved revenue and margins from the orders booked in the quarter, and GE Healthcare is starting to overcome the cost increase hit in 2026.

Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends GE HealthCare Technologies. The Motley Fool has a disclosure policy.

Key Takeaways GEHC posted adjusted EPS of $1.13 in Q2, up 6.6%, as pricing and productivity supported results.PDx revenues rose 15.6% and AIS gained 7.9%, while PCS revenues declined 13.3%.GEHC reaffirmed 2026 organic growth of 3%-4% and adjusted EPS guidance of $4.80-$5.00. GE HealthCare Technologies Inc. (GEHC - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) of $1.13, which beat the Zacks Consensus Estimate of $1.04 by 8.7%. The bottom line increased 6.6% year over year, aided by commercial execution, pricing and productivity gains.

GAAP EPS in the quarter was $1.24, up 16.5% from the year-ago level.

GEHC shares were up 8.3% in pre-market trading. Year to date, shares of the company have lost 21.9% compared with the industry’s 17.1% decline. However, the S&P 500 Index has risen 8.1% in the same period.

Image Source: Zacks Investment Research

GEHC's Revenue Growth Gains MomentumRevenues of $5.29 billion increased 5.7% year over year on a reported basis and 3.5% organically. The top line surpassed the Zacks Consensus Estimate by 0.7%. Revenue growth was led by Pharmaceutical Diagnostics (PDx) and Advanced Imaging Solutions (AIS), along with strength in the United States, EMEA and Rest of World markets. However, growth was partially offset by a decline in the Patient Care Solutions (PCS) segment.

Total company orders increased 11.1% year over year organically. The book-to-bill ratio was 1.15X, indicating rising orders compared to shipments, with backlog reaching a record $23.9 billion. Management cited order growth across every segment, supported by strong commercial execution and adoption of new products.

GE HealthCare’s Q2 Segmental DetailsPharmaceutical Diagnostics revenues increased 15.6% year over year to $843 million. Growth was supported by higher contrast-media volumes, pricing and U.S. radiopharmaceutical demand. Segment EBIT was $250 million, up 16.9% year over year.

Advanced Imaging Solutions revenues increased 7.9% year over year to $3.77 billion. Growth was supported by CardioVascular and Interventional Solutions, computed tomography and Molecular Imaging. Segment EBIT was $525 million, up 15.4% year over year.

Patient Care Solutions revenues declined 13.3% year over year to $675 million. Management attributed the decline primarily to operational and fulfillment challenges, despite strong first-half orders that indicated healthy customer demand.

GEHC's Margin and Cash Flow ImproveNet income margin expanded 90 basis points to 10.6%. However, net income margin was negatively impacted due to PCS weakness and inflation in memory chips, oil and freight costs.

Cumulative cash flow from operating activities at the end of the second quarter was $458 million compared with $344 million a year ago.

GE HealthCare’s Financial PositionGEHC exited the second quarter with cash, cash equivalents and restricted cash of $2.11 billion compared with $2.28 billion in the previous quarter.

Total assets increased to $37.25 billion from $37.12 billion on a sequential basis.

GE HealthCare Reaffirms 2026 GuidanceGE HealthCare reaffirmed its guidance for 2026.

The company still expects organic revenue growth of 3-4% in 2026. It anticipates adjusted EPS to be in the range of $4.80-$5.00, implying 4.6%-9.0% year-over-year growth, as expected previously.

Management anticipates approximately $250 million of inflation associated with memory chips, oil and freight and other components, but expects pricing and cost actions to offset more than half of that impact.

The Zacks Consensus Estimate for 2026 revenues and EPS is pegged at $21.71 billion and $4.89, respectively.

GE HealthCare’s Growth Strategy and Innovation OutlookGE HealthCare delivered solid second-quarter 2026 results, with both earnings and revenues surpassing the Zacks Consensus Estimate. Growth was driven by strong execution in Pharmaceutical Diagnostics and Advanced Imaging Solutions, supported by healthy demand across the United States, EMEA and Rest of World. However, weakness in Patient Care Solutions, along with inflation in memory chips, oil and freight, weighed on margins. The company is taking focused actions to improve PCS execution and supply performance while reviewing strategic options to maximize its long-term value.

Management expects pricing, productivity and cost-control initiatives under its Heartbeat operating model to offset anticipated inflationary impact. The company consolidated Imaging and Advanced Visualization Solutions into the new Advanced Imaging Solutions segment and is integrating its Global Markets organization to create a more connected imaging ecosystem and strengthen commercial capabilities. Its growth strategy remains centered on precision care, innovation-led revenue expansion and business optimization.

GEHC formed a $500 million Care Alliance with Catholic Health, expanded theranostics collaborations and installed the first StarGuide GX system at Essen’s Nuclear Medicine Center of Excellence. The company is advancing cloud-enabled enterprise imaging, AI-assisted radiation therapy planning through MIM Contour ProtégéAI+ 2.0 and quantitative PET imaging with MIM KineticID. Robust U.S. radiopharmaceutical demand remains another growth avenue, with Flyrcado positioned to generate more than $500 million annually and Vizamyl targeted to exceed $200 million by 2028. GEHC’s gadolinium-free MRI contrast-agent trial is also progressing, strengthening its focus on precision care and next-generation diagnostic solutions.

GEHC’s Zacks Rank & Stocks to ConsiderGE HealthCare has a Zacks Rank #3 (Hold) at present.

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.

McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.

29.7.2026 16:27, F, LII, GRMN, VRT, GEHC

Index Dow Jones -1,37 % na 52024,45 b. S&P 500 -0,58 % na 7385,46 b. Nasdaq Composite -0,77 % na 24686,37 b.

Nejsledovanější americké indexy v úvodu středeční seance ztrácejí. Obchodníci na Wall Street se připravují na rozhodnutí Fedu, zatímco ropa zdražuje. Trh se zároveň chystá na výsledky hospodaření dvou z největších investorů do datacenter pro umělou inteligenci, a to společností Meta Platforms a Microsoft. Výsledková sezóna je v plném proudu. Své výsledky mimo jiné zveřejnily společnosti SK Hynix (+0,22 %), KLA (-7,1 %), Seagate (+0,8 %), Procter & Gamble (-2,8 %), SoFi Technologies (-10,2 %) a Visa (+0,5 %). Podrobnosti naleznete v jednotlivých zprávách.

Akcie společnosti Garmin posilují o 17 % poté, co tento výrobce zařízení s GPS zvýšil svůj celoroční výhled pro forma zisku na akcii, čímž překonal průměrný odhad analytiků. Ten nyní očekává ve výši 10,00 USD, zatímco dříve projektoval 9,35 USD a trh odhadoval 9,62 USD.

Akcie společnosti GE Healthcare rostou o 12 % poté, co tento výrobce rentgenových zařízení vykázal za druhé čtvrtletí očištěný zisk na akcii, který překonal průměrný odhad analytiků. Firma rovněž zaznamenala poměr přijatých objednávek k tržbám (booking ratio), který překonal očekávání. Očištěný zisk na akcii dosáhl 1,13 USD při konsensu 1,04 USD. Poměr přijatých objednávek k tržbám dosáhl 1,15 nad konsensem 1,06.

Akcie společnosti Ford ve středu posilují o 7,3 % poté, co tato automobilka vykázala za druhé čtvrtletí očištěný zisk na akcii, který překonal odhady analytiků, a zvýšila svůj výhled očištěného zisku EBIT na rok 2026. Očištěný zisk na akcii dosáhl 0,42 USD na odhady 0,36 USD a očištěný zisk EBIT společnost očekává v rozmezí 10 mld. až 11 mld. USD (dřívější odhad: 8,5 mld. až 10,5 mld. USD), konsensus: 9,46 mld. USD.

Naopak oslabují akcie společnosti Lennox o 19 % poté, co tento výrobce topných a chladicích systémů snížil svůj celoroční výhled zisku na akcii. Ten nyní očekává v rozmezí 23 až 24 USD oproti předchozímu rozpětí 23,5 až 25,0 USD.

Ztrácejí také akcie výrobce napájecích a chladicích zařízení Vertiv Holdings (-12 %) po reportu výsledků za 2Q. Společnost vykázala čisté tržby a růst organických tržeb pod konsensem analytiků. Analytici nadále vidí silné poptávkové trendy, avšak analytici z Morgan Stanley upozornili, že problémy jako přetížení dodavatelských řetězců představují hrozbu pro výhled organického růstu společnosti ve druhé polovině roku. Čisté tržby ve 2Q dosáhly 3,27 mld. USD, tedy pod odhady 3,39 mld. USD. Organický růst tržeb dosáhl 17,8 % při konsensu 24,7 %.

Index S&P 500 -0,58 % na 7385,46 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Energie +2,6 % Průmysl -1,6 % Nezbytná spotřeba +0,3 % Základní materiály -1,2 % Zdravotní péče +0,1 % Informační technologie -0,9 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Garmin (GRMN) +17 % Lennox International (LII) -19 % GE HealthCare Technologies (GEHC) +12 % Masco Corp (MAS) -12 % Cognizant Technology Solutions Corp (CTSH) +8,0 % Vertiv Holdings (VRT) -12 % Ford Motor (F) +7,3 % Humana (HUM) -8,2 % Amphenol Corp (APH) +6,3 % Bunge Global SA (BG) -7,2 % Zdroj: Bloomberg

Michal Bárta
Fio banka, a.s.
Prohlášení

GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its diagnostic and imaging devices and ​refunds of tariffs imposed under U.S. President Donald Trump.

GE HealthCare Technologies (GEHC - Free Report) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +8.65%. A quarter ago, it was expected that this medical technology company would post earnings of $1.07 per share when it actually produced earnings of $0.99, delivering a surprise of -7.48%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

GE HealthCare, which belongs to the Zacks Medical - Products industry, posted revenues of $5.3 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.41%. This compares to year-ago revenues of $5.01 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

GE HealthCare shares have lost about 21.8% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for GE HealthCare?While GE HealthCare has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for GE HealthCare was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.25 on $5.4 billion in revenues for the coming quarter and $4.89 on $21.71 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Insulet (PODD - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.

This maker of insulin infusion systems is expected to post quarterly earnings of $1.38 per share in its upcoming report, which represents a year-over-year change of +18%. The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level.

Insulet's revenues are expected to be $786.82 million, up 21.2% from the year-ago quarter.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the second quarter ended June 30, 2026. GE HealthCare President and CEO Peter Arduini said, “We delivered record orders and backlog in the second quarter, with orders growth across every segment, demonstrating strong commercial execution, including the adoption of new products. In Patient Care Solutions, while we are focused on returning the business to growth and profitability, we are reviewing strategi.